Lindis Biotech

Lindis Biotech is a German, privately-held biotech founded in 2018, advancing its proprietary Triomab® bispecific antibody platform. The platform generates trifunctional antibodies that engage T-cells and accessory immune cells (like macrophages and NK cells) against tumors, aiming for a potent, multi-mechanistic attack with potential vaccination-like effects. As a clinical-stage company, it is pre-revenue and is actively seeking licensing and co-development partnerships to advance its pipeline.

Triomab® platform for generating trifunctional, bispecific antibodies that engage T-cells (via CD3) and accessory immune cells (via Fc region) simultaneously against tumor-associated antigens, aiming for potent tumor killing and induction of long-term anti-tumor immunity.

Lindis competes in the crowded bispecific T-cell engager field against major players like Amgen (Blincyto) and numerous biotechs. Its differentiation is the trifunctional design incorporating Fc-mediated accessory cell engagement, which aims to improve safety and efficacy through physiological co-stimulation and induction of immunologic memory.